MA51309A - Procédé cellulaire quantitatif pour déterminer l'activité biologique d'un ligand anti-cd26 - Google Patents
Procédé cellulaire quantitatif pour déterminer l'activité biologique d'un ligand anti-cd26Info
- Publication number
- MA51309A MA51309A MA051309A MA51309A MA51309A MA 51309 A MA51309 A MA 51309A MA 051309 A MA051309 A MA 051309A MA 51309 A MA51309 A MA 51309A MA 51309 A MA51309 A MA 51309A
- Authority
- MA
- Morocco
- Prior art keywords
- ligand
- determining
- biological activity
- cellular process
- quantitative cellular
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
- G06F17/10—Complex mathematical operations
- G06F17/18—Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Data Mining & Analysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mathematical Physics (AREA)
- Pure & Applied Mathematics (AREA)
- Computational Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Toxicology (AREA)
- Mathematical Optimization (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mathematical Analysis (AREA)
- Organic Chemistry (AREA)
- Databases & Information Systems (AREA)
- Software Systems (AREA)
- Probability & Statistics with Applications (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Algebra (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT201700148959 | 2017-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51309A true MA51309A (fr) | 2021-03-31 |
Family
ID=61868790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051309A MA51309A (fr) | 2017-12-22 | 2018-12-21 | Procédé cellulaire quantitatif pour déterminer l'activité biologique d'un ligand anti-cd26 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11959913B2 (fr) |
| EP (1) | EP3729085B1 (fr) |
| JP (2) | JP7366925B2 (fr) |
| KR (1) | KR102747531B1 (fr) |
| CN (1) | CN111433604B (fr) |
| AU (1) | AU2018392227B2 (fr) |
| BR (1) | BR112020012388A2 (fr) |
| CA (1) | CA3085693A1 (fr) |
| DK (1) | DK3729085T3 (fr) |
| ES (1) | ES3056144T3 (fr) |
| FI (1) | FI3729085T3 (fr) |
| HR (1) | HRP20251577T1 (fr) |
| IL (1) | IL275169B2 (fr) |
| LT (1) | LT3729085T (fr) |
| MA (1) | MA51309A (fr) |
| MX (1) | MX2020006488A (fr) |
| PL (1) | PL3729085T3 (fr) |
| PT (1) | PT3729085T (fr) |
| RS (1) | RS67591B1 (fr) |
| SI (1) | SI3729085T1 (fr) |
| TW (1) | TW201930880A (fr) |
| WO (1) | WO2019123410A1 (fr) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002092127A1 (fr) * | 2001-05-11 | 2002-11-21 | Board Of Regents, The University Of Texas System | Therapie a base d'anticorps monoclonaux anti-cd26 contre des affections en lien avec des cellules exprimant le cd26 |
| JP2008164325A (ja) * | 2006-12-27 | 2008-07-17 | Univ Of Tokyo | 免疫調節剤のスクリーニング方法 |
| AR084216A1 (es) * | 2010-12-09 | 2013-05-02 | Sanofi Sa | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit |
| EP2767549A1 (fr) | 2013-02-19 | 2014-08-20 | Adienne S.A. | Anticorps anti-CD26 et leurs utilisations |
| US9845345B2 (en) * | 2015-05-18 | 2017-12-19 | Ab Initio Biotherapeutics, Inc. | SIRP polypeptide compositions and methods of use |
-
2018
- 2018-12-21 MA MA051309A patent/MA51309A/fr unknown
- 2018-12-21 RS RS20251309A patent/RS67591B1/sr unknown
- 2018-12-21 PL PL18836908.6T patent/PL3729085T3/pl unknown
- 2018-12-21 EP EP18836908.6A patent/EP3729085B1/fr active Active
- 2018-12-21 SI SI201831280T patent/SI3729085T1/sl unknown
- 2018-12-21 CN CN201880074445.0A patent/CN111433604B/zh active Active
- 2018-12-21 AU AU2018392227A patent/AU2018392227B2/en active Active
- 2018-12-21 TW TW107146481A patent/TW201930880A/zh unknown
- 2018-12-21 LT LTEPPCT/IB2018/060507T patent/LT3729085T/lt unknown
- 2018-12-21 US US16/768,206 patent/US11959913B2/en active Active
- 2018-12-21 HR HRP20251577TT patent/HRP20251577T1/hr unknown
- 2018-12-21 CA CA3085693A patent/CA3085693A1/fr active Pending
- 2018-12-21 PT PT188369086T patent/PT3729085T/pt unknown
- 2018-12-21 JP JP2020554599A patent/JP7366925B2/ja active Active
- 2018-12-21 DK DK18836908.6T patent/DK3729085T3/da active
- 2018-12-21 KR KR1020207017700A patent/KR102747531B1/ko active Active
- 2018-12-21 FI FIEP18836908.6T patent/FI3729085T3/fi active
- 2018-12-21 BR BR112020012388-9A patent/BR112020012388A2/pt unknown
- 2018-12-21 IL IL275169A patent/IL275169B2/en unknown
- 2018-12-21 WO PCT/IB2018/060507 patent/WO2019123410A1/fr not_active Ceased
- 2018-12-21 MX MX2020006488A patent/MX2020006488A/es unknown
- 2018-12-21 ES ES18836908T patent/ES3056144T3/es active Active
-
2023
- 2023-10-11 JP JP2023175971A patent/JP7529373B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111433604B (zh) | 2023-12-08 |
| IL275169A (en) | 2020-07-30 |
| MX2020006488A (es) | 2020-12-10 |
| WO2019123410A1 (fr) | 2019-06-27 |
| FI3729085T3 (fi) | 2025-12-19 |
| EP3729085B1 (fr) | 2025-11-05 |
| ES3056144T3 (en) | 2026-02-18 |
| BR112020012388A2 (pt) | 2020-11-24 |
| CA3085693A1 (fr) | 2019-06-27 |
| KR20200103003A (ko) | 2020-09-01 |
| PL3729085T3 (pl) | 2026-02-16 |
| HRP20251577T1 (hr) | 2026-02-27 |
| DK3729085T3 (da) | 2025-12-22 |
| JP2024020200A (ja) | 2024-02-14 |
| KR102747531B1 (ko) | 2024-12-27 |
| TW201930880A (zh) | 2019-08-01 |
| CN111433604A (zh) | 2020-07-17 |
| AU2018392227A1 (en) | 2020-07-09 |
| US20200319169A1 (en) | 2020-10-08 |
| RU2020120500A (ru) | 2022-01-24 |
| RS67591B1 (sr) | 2026-01-30 |
| AU2018392227B2 (en) | 2025-05-01 |
| EP3729085A1 (fr) | 2020-10-28 |
| IL275169B2 (en) | 2025-06-01 |
| PT3729085T (pt) | 2025-12-22 |
| JP7529373B2 (ja) | 2024-08-06 |
| US11959913B2 (en) | 2024-04-16 |
| IL275169B1 (en) | 2025-02-01 |
| JP7366925B2 (ja) | 2023-10-23 |
| SI3729085T1 (sl) | 2026-02-27 |
| LT3729085T (lt) | 2026-01-26 |
| JP2021508834A (ja) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50636A (fr) | Compositions et procédés pour inhiber l'activité d'arginase | |
| EP3267995A4 (fr) | Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement de la fibrose | |
| EP3492462A4 (fr) | Composé amino pyrimidine pour inhiber l'activité de la protéine tyrosine kinase | |
| EP3384070A4 (fr) | Procédé d'amélioration de l'activité catalytique | |
| EP3397968A4 (fr) | Inhibiteurs de l'antigène membranaire spécifique de la prostate (psma) à base d'urée, pour imagerie et traitement thérapeutique | |
| EP3349729A4 (fr) | Support stériquement stabilisé pour agents thérapeutiques sous-cutanés, sublinguaux et oraux, compositions et procédés pour le traitement d'un mammifère | |
| EP3494142A4 (fr) | Anticorps anti-siglec-7 pour le traitement du cancer | |
| EP3447137A4 (fr) | Préparation d'enzyme liquide et son procédé de préparation | |
| MA52545A (fr) | Anticorps pour radionucléides chélatés | |
| EP3604515A4 (fr) | Composition pour la production de tagatose et procédé de production de tagatose l'utilisant | |
| EP3409108A4 (fr) | Couvre-lit pour lit d'animaux de compagnie | |
| EP4045036C0 (fr) | Amides hétéroaryle-biphényle pour le traitement de maladies associées à pd-l1 | |
| EP3975693A4 (fr) | Unité de production pour la culture ou la propagation d'organismes | |
| EP3819284A4 (fr) | Catalyseur pour la préparation de 1,2-pentanediol et procédé de préparation de 1,2-pentanediol l'utilisant | |
| EP3509594C0 (fr) | Inhibiteur d'homologue 2 de lysyl-oxydase pour son employ dans le traitement de la myélofibrose | |
| EP3606520A4 (fr) | Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement des troubles coronaires | |
| EP3852617A4 (fr) | Procédés de réversion d'activité de ticagrélor | |
| EP3553057A4 (fr) | Composé (hétéro)arylamide pour inhiber l'activité de la protéine kinase | |
| EP3968989A4 (fr) | Composé pour le traitement de la goutte ou de l'hyperuricémie | |
| EP3466542A4 (fr) | Cuve pour centrifugeuse et procédé d'isolation de svf utilisant celle-ci. | |
| MA53501A (fr) | Inhibiteurs de pde9 pour le traitement de la drépanocytose | |
| EP3426254A4 (fr) | Utilisation d'inhibiteurs de braf pour le traitement de réactions cutanées | |
| EP3844171A4 (fr) | Amplificateurs de l'activité de la neurolysine | |
| MA53014A (fr) | Composés améliorant l'activité du protéasome | |
| EP3859332A4 (fr) | Procédé de dosage d'hémoglobine glyquée (%) |